By: pennybuster1 $$$$$
22 Dec 2001, 01:22 AM EST Msg. 944 of 945
ragingbull.lycos.com
The Company 2 Watch........
Happy Holiday's.. :) Inside.....
GMED .08
GenoMed, Inc.
(GMED : Pink Sheets : $0.08)
A Company Focused On Identifying Those Genes Responsible For Causing
Serious Illnesses Such As Diabetes, Kidney Disease & Cancer
GenoMed Has A Proven Track Record Of Genetic Research, Discoveries &
Successful Treatments
We Believe That GMED Knows How To Find Genes Responsible For More Than
80 Common Diseases
CORPORATE INFORMATION
Website: genomedics.com
Shares O/S: 116,310,000
Public Float: 103,810,000
52-week Range: $0.05 by $0.14
Last Trade: $0.09
Investor Relations: Craig Hall (941-366-6677)
CHall@FloridaFunds.com
ADDITIONAL COMPANY HIGHLIGHTS
GenoMed already owns three potential blockbuster clinical provisional
patents that are ready for immediate licensing.
Scientific data developed by GMED researchers strongly suggests that
GenoMed has identified a class of SNPs that appear to cause more than 80
common diseases.
GMED’s research strategy and methodology has already yielded
discoveries; genomics-based medication can delay or even reverse life-threatening
illnesses such as diabetes, kidney disease and high blood pressure.
Introduction
We’re a lot closer to being able to identify the causes of many major,
debilitating and life-threatening diseases like cancer, diabetes and
kidney disease than most people are probably aware of.
At the forefront of this tremendous advance in medical research is a
newly-listed company: GenoMed, Inc. (OTC : GMED) where researchers are
confident that they are very close to developing DNA-testing and
genomics-based diagnostic methods that will determine who is genetically
"at-risk" for developing many common but serious diseases.
GenoMed believes that it will be successful in its quest to identify
the optimum medications and dosages for treating, arresting, and in many
cases, reversing these life-threatening diseases.
Longer-term, GenoMed’s ultimate goal is to know enough about a person's
genetic predisposition to disease to keep the disease from occurring.
So, is this fiction? Fantasy?
Hardly….
GenoMed’s Chief Medical Officer, Dr. David Moskowitz has demonstrated
the (www.genomedics.com/index…directors), clinical effectiveness of
identifying a disease-associated gene and developing effective treatments
using existing medications.
GenoMed’s Scientists Have Already Developed Genomics-Based Therapies
With Very Positive Initial Results
In 1993, Dr. David Moskowitz, GenoMed’s Chief Medical Officer, first
discovered that angiotensin I-converting enzyme (ACE; drugs against this
enzyme are called "ACE-inhibitors") was a "master" disease gene.
ACE was subsequently found to be associated with about 40 common but
serious diseases such as Type 2 diabetes (and its complications) and
various forms of cancer.
Armed with this knowledge, Dr. Moskowitz subsequently treated his 1,000
patients and achieved some very dramatic results by applying the
concept that diseases can be cured, arrested, or even reversed by modifying
(medicating) the malfunctioning gene(s)..
For example, the rate of progression of kidney disease among Dr.
Moskowitz’s patients due to high blood pressure was reduced by an average of
400% in both African American and Caucasian men.
Through Dr. Moskowitz’s treatment programs, patients expected to reach
dialysis in four years were delayed by an average of 16 years in
reaching end-stage kidney disease.
Patient outcomes for kidney failure due to type 2 diabetes,
atherosclerotic peripheral vascular disease, and emphysema were equally exciting.
Now, having formed GenoMed and raised capital to continue their
research, Dr. Moskowitz and the GMED team will be looking to extend their
success with the ACE "master" disease gene, and fast-tracking the
identification of many, many more disease-causing genes.
Some Background Information On The Science Of Medical Genomics
Genes are the building blocks of life and are responsible for the
production of proteins that make up a cell's structure and operate its vital
chemistry.
Each cell's nucleus holds 46 chromosomes in 23 pairs, containing
approximately 40,000 genes. This set of
genes, the human genome, contains all the instructions for creating a
human being.
The protein products of these genes then carry out those instructions
within every cell of the human body.
The goal of medical genomics is to prevent or cure disease in the
individual patient by exploiting knowledge of these disease-predisposition
genes (see genomedics.com…science).
In
In the not too distant future, a routine visit to the doctor will
likely include the extraction of a blood sample from the patient. The
patient’s DNA would then be isolated and analyzed, allowing the physician to
predict the patient’s likelihood of coming down with any of a number of
common chronic diseases during the patient’s lifetime.
Bottom-line, what GenoMed is working on may well result in early
diagnosis of disease and the ability for people to maintain their health,
using safe but extremely genomedics.com…medicine)
effective drugs.
GenoMed’s goal is to construct a comprehensive list of disease-causing
genes so that doctors can predict with reasonable confidence what
diseases a person may experience during their lifetime.
GenoMed believes that the place to look for disease-causing mutations
is in the non-coding region of the genes, especially the parts which
determine when the gene is turned on or off (the so-called "regulatory
regions").
Using bio-informatics techniques, the regulatory regions of most of the
40,000 genes can now be deduced using computers. Already-published
variations in regulatory regions can be catalogued, again using computers.
For genes which seem especially important, new variations in their
regulatory regions can be discovered by re-sequencing, a process that
effectively "stretches" DNA by using a number of DNA samples from unrelated
people.
The Type Of Genomics Research That GenoMed Is Doing Is Analagous To
Fishing - The Key To Success
Is In Knowing Where To Look….
Think of GMED’s on-going research into identification of disease genes
as being analagous to fishing - the bigger the net that you are able to
cast, the greater the chances are that you will catch some fish.
The "ocean" that GenoMed is working in is the Human Genome, which
contains some 40,000 genes and more than three billion "letters". Within
this ocean of genetic data, a disease-causing variation can be something
as small as a single "letter" - also known as a single nucleotide
polymorphism or SNP (pronounced "snip").
The reason why one person gets cancer but their neighbor gets heart
disease is generally believed to be contained in the differences between
the letters of their DNA. The question is "which few SNP’s account for
their different diseases? " And how do you find them in a sea of three
billion total letters?
Again, finding disease genes is like fishing in the ocean: the larger
the net, the more likely you are to catch a fish.
However, since no one company has the resources or manpower to search
the entire Human Genome, GMED has decided to do the next best thing:
focusing on where the fish (disease genes) are most likely to be…
Common diseases are exquisitely complicated - the result of perhaps
more than 100 SNPs in dozens of different genes, many of which interact
with one
another. So many SNPs are involved that each one hardly stands out.
GenoMed believes that the only way to find these SNPs is to trawl a net
that catches disease fish specifically. This means going after the
disease-causing SNPs themselves.
Why? To the best of our knowledge, no other genomics research company
is taking this approach…
Well, quite simply, GenoMed believes that enough disease-associated
SNPs have been found in regulatory regions to justify focusing on this
part of each gene.
Whereas other companies use "marker" SNPs to try to get close to the
disease-causing region of a gene, GenoMed is going to use SNPs, which it
believes have a high likelihood of being the cause of a specific
disease (i.e. of being functional in and of themselves, and not just being
markers).
GenoMed’s Research Strategy
Is Actually Quite Straight-Forward
GenoMed is using a straight-forward approach (and off-the-shelf
technology) to identify which gene (or groups of genes) cause diseases.
First, SNPs that appear at a much higher frequency among patients with
a particular disease ("cases") than among people of the same ethnic
group without the disease ("controls") are identified as
"disease-associated SNPs".
SNPs that occur significantly less often among patients (cases) than
controls will be labeled "protective SNPs" (i.e., these make a particular
disease much harder to get.
How significant the association is between a SNP and the disease can be
measured by standard statistic techniques, and GenoMed has assembled a
team of some of the top genetic statisticians and molecular
epidemiologists in the world to perform this complex analysis.
GMED Is Focusing Its Research
On A Number Of Serious Diseases
GenoMed is currently collecting and analyzing genetic data for the
following (www.genomedics.com/index…diseases) diseases: Type 2 diabetes
(also called "adult-onset diabetes"); high blood pressure; end-stage
kidney disease (due to type 2 diabetes or high blood pressure); and, cancers
(breast, lung, prostate & colon).
DNA Samples Are Being Collected From Various Ethnic, Gender & Racial
Groups
Research has conclusively established that disease genes can vary
depending on a person’s gender and ethnic/racial group.
To ensure that its diagnostic research is complete and comprehensive,
GMED is already or plans soon to be collecting DNA data from the
following patient populations: Caucasians (USA & Russia); African-Americans
(United States); Hispanics (United States); and, Asians (Korea).
We Believe That GenoMed Is On The Verge Of Making A Series Of
Discoveries Concerning Which Genes Cause Major Illnesses & Diseases
In our opinion, the scientific data which GenoMed's researchers and
others have discovered through the past eight years of clinical-oriented
studies provide more than enough evidence to justify GMED’s belief that
it has identified a class of SNPs that appear to cause most common
diseases (www.genomedics.com/index..advantages)
We believe that GMED is on the right track, and, in the not too distant
future, will be able to identify the causes of common diseases at the
genetic level.
By knowing where to look for disease-causing variations in genes (in
the "regulatory regions" of genes), GenoMed
on-track to find body’s "on / off" switches. GMED’s research methods
are novel (actually, everyone else is taking a far different approach).
Lastly, GenoMed is compiling a huge database of DNA samples from actual
patients around the world and is using ultra-high throughput genotyping
in the production of their data.
There’s going to be a huge payday for the first company to identify the
gene (or group of genes) that triggers a major illness like diabetes or
cancer…
In closing, what will this mean for the average person?
GenoMed hopes to discover a comprehensive list of disease-causing genes
so that doctors can predict with reasonable confidence what diseases a
person may experience during their lifetime. Drugs developed and
directed specifically against these disease-causing genes are expected to
halt these diseases in their tracks.
As Dr. Moskowitz has conclusively proven with the ACE gene, knowledge
of disease-causing genes can also help people with already-established
diseases.
Early detection will allow doctors to halt the disease process at an
early-enough stage so that we might even be able to prevent the disease
from occurring. Keep in mind that Dr. Moskowitz has already proven that
this approach works - witness the great success that he has had with
patients suffering from kidney disease, poor circulation, and emphysema
by prescribing an effective dose of ACE-inhibitor medications...
GenoMed’s goal is nothing short of a medical revolution: they aim to
change the way medicine is practiced. Instead of waiting for symptoms to
develop, doctors will soon be able to diagnose disease before any signs
are visible.
Just as Microsoft brought us the Age of Personal Computing, GenoMed
intends to be a leader in the Era of Preventive Molecular Medicine.
Sources of Additional Information
GenoMed’s "revolutionary genomics research" was recently profiled in
the St. Louis Business Journal - the complete story can be found at
(http://www.stlouis.bcentral.com/stlouis/stories/2001/11/26/daily39.html).
GenoMed’s recent press releases can be accessed at the company’s
website: genomedics.com…press.
GMED
GMED anticipates that it will file a Form 10-SB with the U.S.
Securities & Exchange Commission by January 2002; the complete filing will be
available on-line at sec.gov. Information on the law firm handling
GMED’s filings can be found at: hldpa.com
Investors and other interested parties are also encouraged to visit the
Company’s web site (http://www.genomedics.com) and/or contact Craig
Hall @ (941) 366-6677 (e-mail: chall@floridafunds.com).
Richard Kranitz Joins GenoMed, Inc. as a Member of its Board of
Directors and as Corporate Secretary
SARASOTA, Fla., Dec 13, 2001 (BUSINESS WIRE) -- GenoMed Inc. ("the
Company" or "GenoMed") (Pink Sheets:GMED), a St. Louis based medical
genomics biotechnology company, announced today that Richard Kranitz has
accepted a position as a member of the Company's Board of Directors and as
Corporate Secretary.
Richard Kranitz, an attorney in private practice since 1970, is a 1969
graduate of the University of Wisconsin Law School and served for a
year as an assistant to a federal judge. During the past 30 years he has
served as a director of a number of private companies, and professional,
civic, and charitable organizations. Since 1990, Mr. Kranitz has been a
director of the Grafton State Bank, a subsidiary of Merchants &
Manufacturers Bancorporation (symbol:MMBI). He has also served as a director
of, among other public companies, Harp & Eagle, Ltd. (symbol:HARP) and
Mentor Capital Consultants, Inc. (symbol:MCAP). Mr. Kranitz has served
for a number of years as a director of the Mental Health of Ozaukee
County, Inc., a non-profit organization promoting mental health and care
for the mentally ill.
Mr. Kranitz's law firm concentrates in business and securities matters,
including mergers & acquisitions, private and public securities
offerings, investment funds, and corporate organizational matters. The firm's
clientele is located around the United States as well as several
foreign countries.
Jerry White, GenoMed's Chief Executive Officer, stated that, "I am
honored to announce to our shareholders that Mr. Richard Kranitz has
accepted the position as a Director and Corporate Secretary. Mr. Kranitz
brings a wealth of knowledge to GenoMed in key areas and is a true asset to
the Company and its shareholders. We are confident that we have added
another key component to our corporate structure."
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of
disease genes into better patient outcomes as rapidly and as safely as
possible. The Company's business model specifically links improved
patient outcomes to Company revenues through clinical treatment and genetic
diagnoses of diseases.
For additional information please visit genomedics.com
and/or contact Craig Hall at 941/366-6677 or email at
chall@floridafunds.com.
This press release contains forward looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, including those statements pertaining
to the beneficial nature of Mr. Kranitz joining the Company as a member
of the Board of Directors and as Corporate Secretary. The words or
phrases "would be," "will allow," "intends to," "will likely result," "are
expected to," "will continue," "is anticipated," "estimate," "project,"
or similar expressions are intended to identify "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from those projected
in the forward looking statements as a result of a number of risks and
uncertainties. Among other things, competition from existing or new
competitors will impact our business; our research and development is
subject to economic, regulatory, governmental, and technological factors.
Statements made herein are as of the date of this press release and
should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, we do not undertake, and specifically disclaims
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances after the
date of such statement.
CONTACT: GenoMed Inc., Sarasota
Craig Hall, 941/366-6677
URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Biotech Reaps Venture Cash Despite Tech Meltdown
By Jim Christie
dailynews.yahoo.com
SAN FRANCISCO (Reuters) - Venture capital firms are jumping on the biotechnology bandwagon, pumping cash into start-up labs and related information technology, even as they slash financing for ventures in other technology sectors.
www.genomicsfund.com/portfolio.html
Fund Services,Inc
P.O BOX 26305
RICHMOND, VA 23260
PH# 1-877-433-GENE
Want Genomics? Why Buy Biotech?
As you can see by our portfolio, listed in full below, GenomicsFund.com is sharply focused on the Genomics Industry. Biotech, Life Sciences and Health funds, in contrast, often have a substantial portion of their portfolio in mature pharmaceutical companies, medical device manufacturers, generic drug makers, and even hospitals and HMO's. We believe the rapidly emerging Genomics Industry will provide better investment opportunities than those found in the broader Life Sciences Industry. That's why we're 100% Genomics.
Portfolio (November 15, 2001)
It is the current policy of the Investment Adviser to maintain a 100% invested position in a diversified portfolio of Genomic related securities. The fund does not presently have any holdings in non-genomic companies, although it has the flexibility to do so in the future. Securities denoted in bold face indicate a position greater than 5% of the fund's assets.
Pharmagenomics
Companies using genomic discoveries to create a new generation of pharmaceuticals and therapeutics. Approximately 51% of the portfolio.
- Gilead Sciences (GILD) Foster City, CA
- Human Genome Sciences (HGSI) Rockville, MD
- Millennium Pharmaceuticals (MLNM) Cambridge, MA
- Isis Pharmaceuticals (ISIP) Carlsbad, CA
- Cubist Pharmaceuticals (CBST) Cambridge, MA
- Medimmune (MEDI) Gaithersburg, MD
- Ribozyme Pharmaceuticals (RZYM) Boulder, CO
- 3 Dimensional Pharmaceuticals (DDDP) Exton, PA
- Transgene SA (TRGNY) Strasbourg, France
- Vertex Pharmaceutical (VRTX) Cambridge, MA
Monoclonal Antibodies
Companies developing monoclonal antibodies. The increasing number of specific antibody targets discovered by genomics-based technologies will speed the development of this class of therapeutics, many of which are near commercialization. Approximately 36% of the portfolio.
- Imclone Systems (IMCL) New York, NY
- Medarex (MEDX) Princeton, NJ
- Protein Design Labs (PDLI) Fremont, CA
- Abgenix (ABGX) Fremont, CA
Bioinformatics
Companies developing comprehensive genomic, DNA, and protein database libraries for analysis and sale. Approximately 7% of the portfolio.
- Celera Genomics (CRA) Rockville, MD
- Curagen (CRGN) New Haven, CT
Analysis & Platform Technologies
Companies using advanced technologies to develop instrumentation, equipment, techniques, and software to aid in gene discovery, sequencing, and statement, as well as DNA analysis. Approximately 6% of the portfolio.
- Affymetrix (AFFX) Santa Clara, CA
- Applied Biosystems Group (ABI) Norwalk, CT
- Large Scale Biology (LSBC) Vacaville, CA
- Lexicon Genetics (LEXG) The Woodlands, TX
- Visible Genetics (VGIN) Toronto, Canada
--------------------------------------------------------------------------------
Why Genomics?
Welcome to the world of genomics -- an exciting place where every day seems to bring new discoveries. These discoveries could profoundly affect your life. And, more significantly, the lives of generations to come.
Perhaps you've read about the Human Genome Project -- the quest to decode an entire set of human genes -- which was funded by the U.S. Department of Energy starting in 1986 and joined in 1990 by the National Institutes of Health. Today, myriad private and public companies, realizing both the scientific and economic impact the new discoveries will carry, have joined in and are accelerating the work. Many believe the entire human genome will be mapped as early as 2000. It will stand as one of mankind's greatest scientific achievements.
GenomicsFund.com believes significant opportunities exist in this emerging, exciting field. We'll try to identify those companies that can profit from the new technologies.
As with all endeavors, investing in GenomicsFund.com involves many risks. It is not suitable for all investors. Please carefully review the Risk Factors section of the prospectus before you invest or send money.
Would you like to learn more about the field of genomics? Please visit the Genomics 101 Classroom on this site. In addition to information about the history, science, and impact of genomics, Genomics 101 contains links to breaking genomic news. Please visit us soon and often. |
